目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T63985 | |||
Trimetrexate glucuronate (NSC 352122) 是一种叶酸拮抗剂,能够抑制二氢叶酸还原酶 (dihydrofolate reductase),进而阻断嘌呤核苷酸和胸苷酸的合成,影响 DNA 和 RNA 合成,表现出潜在的抗肿瘤效果。 | |||
T62217 | |||
Tubulin polymerization-IN-9 是一种微管蛋白 (tubulin) 的有效抑制剂 (IC50: 1.82 μM)。Tubulin polymerization-IN-9 能够将 K562 细胞的细胞周期停滞在 G2/M 期,并诱导其凋亡 (apoptosis) 及线粒体去极化。Tubulin polymerization-IN-9 表现出强大的抗血管和抗肿瘤作用。 | |||
T63135 | |||
FLT3/CDK4-IN-1 是一种高度选择性的、有效的、口服具有活力的 FLT3/CDK4 双重抑制剂,作用于 FLT3 (IC50: 7 nM) 与 CDK4 (IC50: 11 nM)。FLT3/CDK4-IN-1 在体内具有良好的抗肿瘤效果,对某些癌细胞表现出抗增殖作用。 | |||
T63182 | |||
BTK-IN-15 是一种新型的、口服具有活力的布鲁顿酪氨酸激酶 (BTK) 抑制剂,能够抑制 BTK (IC50: 0.7 nM)。BTK-IN-15 可诱导癌细胞凋亡,具有良好的激酶选择性和抗肿瘤活性。 | |||
T62717 | |||
A2AAR/HDAC-IN-2 是一种有效的 A2AAR/HDAC 双重抑制剂。A2AAR/HDAC-IN-2 对 A2AAR 表现出良好的亲和力 (Ki:10.3 nM), 能够良好的抑制 HDAC1 (IC50:18.5 nM). A2AAR/HDAC-IN-2 能够用于研究抗肿瘤。 | |||
T71287 | |||
CDKI-83 is a potent CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 <1 μM, and is capable of inducing apoptosis in A2780 human ovarian cancer cells as determined by the activated caspase-3, Annexin V/PI double staining and accumulated cells at the sub-G1 phase of cellcycle. The research results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent. | |||
T64010 | |||
ABN401 是一种高效的、选择性的、ATP 竞争性的 c-MET 抑制剂 (IC50: 10 nM)。ABN401 对嗜 MET 的癌细胞表现出细胞毒性。ABN401 对肿瘤组织中 c-MET 的磷酸化表现出抑制作用。ABN401 能够用于抗癌的研究。 | |||
T64090 | |||
Regorafenib (BAY 73-4506) mesylate 是一种口服具有活力的多靶点受体酪氨酸激酶 (tyrosine kinase) 抑制剂,能够抑制VEGFR1/2/3 (IC50=13/4.2/46 nM),PDGFRβ (IC50: 22 nM),Kit (IC50: 7 nM),RET (IC50: 1.5 nM) 和 Raf-1 (IC50: 2.5 nM)。Regorafenib mesylate 具有强大的抗肿瘤和抗血管生成作用。 | |||
T63076 | |||
IHMT-TRK-284 (Compound 34) 是一种有效的、口服具有活力的 type II TRK kinase 抑制剂,能够作用于 TRKA (IC50: 10.5 nM)、TRKB (IC50: 0.7 nM)、TRKC (IC50: 2.6 nM)。IHMT-TRK-284 在激酶组中表现出良好的选择性,体内具有良好的抗肿瘤作用。 | |||
T64058 | |||
PLK1/BRD4-IN-1 (9b) 是一个口服具有活力的 PLK1 (IC50: 22 nM) 和 BRD4 (IC50: 109 nM) 双重抑制剂。PLK1/BRD4-IN-1 能够诱导细胞凋亡,并使细胞周期阻滞 (cell cycle arrest),将几种增殖相关癌基因的转录下调,并具有良好的体内抗肿瘤作用。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
|
|||||
TMPK-00456 | IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00455 | IGF1R/CD221 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00658 | IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 80.59 kDa (alpha subunit) and 19.28 kDa (beta subunit) and the accession number is G7P9I7.
|